September 16th, 2024; BNCM is excited to announce that the ICU (Intensive Care Unit) Forums conducted by DELEX have reached a Global Audience of almost 200,000 Healthcare Professionals.
Delex Pharma’s ICU Forums, a Continuing Medical Education (CME) initiative, has forged strong webinar partnerships with leading hospitals and medical societies across the Philippines. Notable institutions such as St. Luke’s Medical Center, The Medical City, Makati Medical Center, and Asian Hospital Medical Center are among nearly fifty partners that consistently engage with the platform. The ICU Forums have reached a global audience of almost 200,000 healthcare professionals from over 50 countries and exposure for Delexs products to the global healthcare industry.
The inception of the ICU Forum in 2016 marked a pivotal moment for Delex Pharma in fulfilling its mission to address gaps in critical care. Ms. Ma. Lourdes Monasterio, the Vice President for Marketing, who authored such a program, said, The ICU Forum is a testament to Delex Pharma International Inc.’s commitment to Continuing Medical Education (CME) and its advocacy for Filipino healthcare professionals. This initiative aims to elevate the standard of excellence in treating critically ill patients in ICU settings.
The long-running marketing strategy was initially designed to cater to medical doctors in 2016, providing them with the latest insights and guidelines to improve patient outcomes. Over time, the initiative flourished to include forums specifically tailored for pharmacists in 2017 and nurses in 2019, thereby broadening its reach and impact.
The COVID-19 pandemic brought unprecedented strain to the global healthcare system, including the Philippines. Amid the crisis, Delex Pharma swiftly adapted by transitioning its CME initiative online. The Online ICU Forum became an essential platform for sharing COVID-19 management strategies and the latest clinical research, rapidly increasing global engagement from healthcare providers and significantly boosting brand awareness for the company.
As the world transitions into a post-pandemic era, Delex Pharma remains committed to elevating the standard of care for critically ill patients. The company continues to explore and integrate current innovations, concepts, and practices that align with its mission to provide the highest quality healthcare through the ICU Forum. Ms. Monasterio highlighted that The ICU Forum program will continue to redefine its core purpose and evolve to meet the CME needs of our healthcare providers in the post-pandemic era. By offering hybrid webinars and collaborating with other medical institutions, we aim to bring highly valuable symposia from around the world to the Philippines, just as we did during our last ICU Forum for MDs in March 2024. This initiative will undoubtedly continue to propagate Delex Pharma’s market visibility both locally and globally.
BNCM is an Asset Management Company that secures its assets by investing in companies with strong growth potentials, robust revenues, significant profits, proven track records, and promising business models with highly experienced management teams that will exceptionally qualify for quotation and listing on the OTC or NASDAQ markets within the next 2 to 3 years. The growth of these companies will directly provide more employment opportunities to the communities, improve the country’s economy, and bring greater social change.
For more information, visit: https://www.bncm.net/
DELEX is a Delaware-registered company, and the holding company of DLX Holdings, Inc. (DLX). DLX is a Philippine-based parent company that holds a 60% controlling interest in Delex Pharma International, Inc. an ISO 9001-2015 Certified company, which also holds a controlling interest in JMN Brother’s Pharma Limited, Inc. DLX and its subsidiaries are involved in the development and distribution of pharmaceutical and healthcare products in the Philippines.
For more information, visit: https://delexhealth.com
